A tighter archive for life-science signals.
Search once, then narrow by source or topic.
AbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fight
AbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fight
NIH stops low-dose Xarelto arm of large stroke study due to safety concerns
NIH stops low-dose Xarelto arm of large stroke study due to safety concerns
Is AstraZeneca on track to meet its $80B revenue target?
Is AstraZeneca on track to meet its $80B revenue target?
The fallout from Novo vs. Hims
The fallout from Novo vs. Hims
Shanghai's Cascade gets $72M to pursue MASH, obesity and diabetes drugs
Shanghai's Cascade gets $72M to pursue MASH, obesity and diabetes drugs
Nektar posts one-year eczema success; Pfizer ends malnutrition trial
Nektar posts one-year eczema success; Pfizer ends malnutrition trial
CSL’s Paul McKenzie out, as Gordon Naylor named interim CEO
CSL’s Paul McKenzie out, as Gordon Naylor named interim CEO
AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed back
AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed back
'Bat-sh*t crazy': Biopharma leaders unload on regulatory chaos
'Bat-sh*t crazy': Biopharma leaders unload on regulatory chaos
Hengrui, Kailera push obesity pill ahead on promising mid-stage China data
Hengrui, Kailera push obesity pill ahead on promising mid-stage China data
FDA rejects Regenxbio's Hunter syndrome gene therapy
FDA rejects Regenxbio's Hunter syndrome gene therapy
With scant data, RFK Jr. credits Trump for higher European drug prices
With scant data, RFK Jr. credits Trump for higher European drug prices
QuantX raises $85M Series B from Lilly, Sanofi Ventures
QuantX raises $85M Series B from Lilly, Sanofi Ventures
Despite FDA’s crackdown, pharma is still spending millions on ads
Despite FDA’s crackdown, pharma is still spending millions on ads
Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisition
Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisition
Galux raises $29M Series B; CSL teams up with Memo
Galux raises $29M Series B; CSL teams up with Memo
#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%
#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%
Takeda, Iambic sign multiyear R&D deal for AI drug discovery
Takeda, Iambic sign multiyear R&D deal for AI drug discovery
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page